“Our goal is to use this information to move into a trial that examines whether women with a low baseline risk can be managed without exposing them to magnesium or other tocolytics,” she said.
Dr. Bastek's coresearchers included principal investigator Dr. Michal A. Elovitz, Dr. Sindhu Srinivas, and biostatistician Mary D. Sammel.